CHICAGO -- An antibody-microtubule

 CHICAGO -- An antibody-microtubule inhibitor conjugate improved survival in selected patients with advanced platinum-resistant ovarian cancer compared with standard chemotherapy, representing the first novel drug to do so in a phase III trial for this difficult-to-treat population.